North American Journal of Medical Sciences

REVIEW ARTICLE
Year
: 2015  |  Volume : 7  |  Issue : 1  |  Page : 6--12

Use of oral anti-diabetic agents in pregnancy: A pragmatic approach


Bharti Kalra1, Yashdeep Gupta2, Rajiv Singla3, Sanjay Kalra4 
1 Consultant, Department of Obstetrics and Gynaecology, Bharti Hospital, Karnal, Haryana, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India
3 Consultant, Department of Endocrinology and Metabolism, Saket City Hospital, New Delhi, India
4 Consultant, Department of Endocrinology and Metabolism, Bharti Hospital, Karnal, Haryana, India

Correspondence Address:
Sanjay Kalra
Consultant, Endocrinology and Metabolism, Bharti Hospital, Kunjpura Road, Karnal - 132 001, Haryana
India

Insulin is the gold standard for treatment of hyperglycemia during pregnancy, when lifestyle measures do not maintain glycemic control during pregnancy. However, recent studies have suggested that certain oral hypoglycemic agents (metformin and glyburide) may be safe and be acceptable alternatives. There are no serious safety concerns with metformin, despite it crossing the placenta. Neonatal outcomes are also comparable, with benefit of reductions in neonatal hypoglycemia, maternal hypoglycemia and weight gain, and improved treatment satisfaction. Glibenclamide is more effective in lowering blood glucose in women with gestational diabetes, and with a lower treatment failure rate than metformin. Although generally well-tolerated, some studies have reported higher rates of pre-eclampsia, neonatal jaundice, longer stay in the neonatal care unit, macrosomia, and neonatal hypoglycaemia. There is also paucity of long-term follow-up data on children exposed to oral agents in utero. This review aims to provide an evidence-based approach, concordant with basic and clinical pharmacological knowledge, which will help medical practitioners use oral anti-diabetic agents in a rational and pragmatic manner. Pubmed search was made using Medical Subject Headings (MESH) terms «DQ»Diabetes«DQ» and «DQ»Pregnancy«DQ» and «DQ»Glyburide«DQ»; «DQ»Diabetes«DQ» and «DQ»Pregnancy«DQ» and «DQ»Metformin«DQ». Limits were randomized controlled trials (RCTs) and meta-analysis. The expert reviews on the topic were also used for discussion. Additional information (studies/review) pertaining to discussion under sub-headings like safety during breastfeeding; placental transport; long-term safety data were searched (pubmed/cross-references/expert reviews).


How to cite this article:
Kalra B, Gupta Y, Singla R, Kalra S. Use of oral anti-diabetic agents in pregnancy: A pragmatic approach.North Am J Med Sci 2015;7:6-12


How to cite this URL:
Kalra B, Gupta Y, Singla R, Kalra S. Use of oral anti-diabetic agents in pregnancy: A pragmatic approach. North Am J Med Sci [serial online] 2015 [cited 2021 Oct 20 ];7:6-12
Available from: https://www.najms.org/article.asp?issn=1947-2714;year=2015;volume=7;issue=1;spage=6;epage=12;aulast=Kalra;type=0